2015年11月26日 · In the EMPA-REG OUTCOME trial, we examined the effects of empagliflozin, as compared with placebo, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for ...

RSK inhibition by EMPA appears as a novel direct cardiac target of SGLT2i. Direct cardiac effects of EMPA exert their anti-hypertrophic effect through NHE-inhibition and subsequent RSK pathway inhibition.

2024年5月1日 · The major findings of the present study can be summarized as follows: (1) the SGLT2 inhibitor EMPA negatively regulates various STK in the isolated diabetic heart, with largest reductions in RSK and Aurora A and B kinase activities, (2) EMPA alleviates PE-induced hypertrophy in a cardiac cellular model of hypertrophy, demonstrating direct ...

2017年11月13日 · In the EMPA-REG OUTCOME trial, the sodium glucose cotransporter 2 inhibitor empagliflozin reduced the risk of cardiovascular death by 38% (hazard ratio [HR], 0.62; 95% confidence interval [CI] 0.49–0.77]) and hospitalization for heart failure (HHF) by 35% (HR, 0.65; 95% CI, 0.50–0.85) versus placebo when given in addition to standard of ...

2024年3月24日 · 根据 h9c2 细胞中 bnp 和细胞表面积的评估，empa 可以预防 pe 诱导的肥大。 empa 阻断 pe 诱导的 nhe1 激活。特异性 nhe1 抑制剂 cariporide 也可以预防 pe 引起的肥大，而无需增加 empa 的作用。 empa 阻断 pe 诱导的 rsk 磷酸化。

2022年3月23日 · We showed that EMPA treatment significantly relieved high systolic blood pressure and proteinuria and ameliorated kidney injury in PE mice without affecting fetal outcomes. EMPA also ameliorated podocyte injury and oxidative stress, reduced the expression of SGLT2 and activated the AMPK/SIRT1 signaling pathway in vivo and in vitro .

2024年7月11日 · We assessed the effect of empagliflozin on total (first plus recurrent) events of centrally adjudicated fatal and non-fatal myocardial infarction (MI) using a negative binomial model with robust confidence intervals (CI) that preserves randomization and accounts for the within-patient correlation of multiple events.

2016年1月31日 · エンパグリフロジンは、ハイリスクの2型糖尿病患者においてbaselineの心不全の有無によらず、心不全による入院と心血管死を減少させた。 inclusion criteria：18歳以上、BMI45以下、eGFR>30ml/min/1.73m2、心血管疾患 (2ヶ月以上前の心筋梗塞の既往、CAGまたはMDCTで証明された2枝以上または左冠動脈主幹部の狭窄、2ヶ月以上前のPCI/CABGの既往、2ヶ月以上前の脳梗塞の既往、末梢血管へのstentingやbypassなどの閉塞性動脈硬化症)と診 …

EMPA-REG OUTCOME®︎試験では、心血管疾患を有する2型糖尿病患者に対し、標準的治療にエンパグリフロジンを追加することで、3-point MACE（心血管死、非致死的心筋梗塞、非致死的脳梗塞）を14%、心血管死を38%、心不全入院を35%、全死亡を32%低下させた。

2024年10月25日 · In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease...